Omega Ophthalmics has secured $7.0 million in Series A funding, marking its first institutional round. This capital infusion will support the advancement of its Gemini Refractive Capsule, with the company scheduling an FDA pre-submission meeting. The funding will also facilitate the expansion of its team and further development of its technology.